Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
0(0%)
Results Posted
50%(6 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_4
4
27%
Ph not_applicable
2
13%
Ph phase_2
4
27%
Ph phase_3
2
13%

Phase Distribution

2

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
4(28.6%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(12)
Terminated(2)
Other(1)

Detailed Status

Completed12
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 24 (28.6%)
Phase 32 (14.3%)
Phase 44 (28.6%)
N/A2 (14.3%)

Trials by Status

completed1280%
terminated213%
unknown17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_4

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

NCT04745910
unknownphase_4

Rasburicase Treatment in Chronic Gouty Arthritis

NCT05312268
completedphase_3

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

NCT00199043
completednot_applicable

Uric Acid Effects on Endothelium and Oxydative Stress

NCT03395977
completedphase_2

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

NCT01200485
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT04745910Phase 4

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Completed
NCT05312268Phase 4

Rasburicase Treatment in Chronic Gouty Arthritis

Unknown
NCT00199043Phase 3

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Completed
NCT03395977Not Applicable

Uric Acid Effects on Endothelium and Oxydative Stress

Completed
NCT01200485Phase 2

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Completed
NCT01931527Not Applicable

Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status

Completed
NCT01564277Phase 2

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Terminated
NCT00513474Phase 1

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Completed
NCT00186940

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Completed
NCT00057811Phase 2

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Completed
NCT00607152Phase 3

Rasburicase (Fasturtec) Registration Trial

Terminated
NCT00756964Phase 2

Lowering Serum Uric Acid to Prevent Acute Kidney Injury

Completed
NCT00360438Phase 1

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Completed
NCT00302653Phase 4

Rasburicase in Tumor Lysis Syndrome

Completed
NCT00563771Phase 4

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15